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Abstract
The HIV-1 epidemic in South America is dominated by pure subtypes (mostly B and C) and more than 7 BF and BC
recombinant forms. In Argentina, circulating recombinant forms (CRFs) comprised of subtypes B and F make up more than
50% of HIV infections. For this study, 28 HIV-1 primary isolates were obtained from patients in Buenos Aires, Argentina and
initially classified into subtype B (n = 9, 32.1%), C (n = 1, 3.6%), and CRFs (n = 18, 64.3%) using partial pol and vpu-env
sequences, which proved to be inconsistent and inaccurate for these phylogenetic analyses. Near full length genome
sequences of these primary HIV-1 isolates revealed that nearly all intersubtype BF recombination sites were unique and
countered previous ‘‘CRF’’ B/F classifications. The majority of these Argentinean HIV-1 isolates were CCR5-using but 4 had a
dual/mixed tropism as predicted by both phenotypic and genotypic assays. Comparison of the replicative fitness of these BF
primary HIV-1 isolates to circulating B, F, and C HIV-1 using pairwise competitions in peripheral blood mononuclear cells
(PBMCs) indicated a similarity in fitness of these BF recombinants to subtypes B and F HIV-1 (of the same co-receptor usage)
whereas subtype C HIV-1 was significantly less fit than all as previously reported. These results suggest that the multitude of
BF HIV-1 strains present within the Argentinean population do not appear to have gained replicative fitness following
recent B and F recombination events.
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Introduction
Human immunodeficiency virus type 1 (HIV-1) evolved from
the simian immunodeficiency virus (SIVcpz) predominant in the
subspecies of chimpanzee, Pan troglodytes troglodytes (Ptt) [1–4]. The
transmission events from apes to humans occurred on at least four
separate occasions which is represented by phylogenetic distinct
groups termed M (major), O (outlier), N (non-M, non-O) and P.
HIV-1 group M is responsible for the global pandemic shown
clearly by its divergence into nine ‘‘pure’’ clades or subtypes (A-D,
F-H, J and K), 63 circulating recombinant forms (CRF) (www.hiv.
lanl.gov) and a myriad of unique recombinant forms (URF).
Globally, CRFs account for about 10–20% of all new HIV-1
infections while URFs are responsible for over 30% of infections in
regions where two or more subtypes co-circulate [2,3]. Inter-
subtype recombinants are clearly contributing to HIV-1 evolution
and may ultimately result in complete disappearance of the ‘‘pure’’
HIV-1 subtypes [5], which in fact originated from earlier SIV/
HIV recombination events [6].
The prevalence of HIV-1 subtypes and CRFs in the human
population varies by geographical region and can be influenced by
various socio-cultural factors as well as virus-host genetics (founder
effects and host restrictive factors) [7]. Although subtype B is
dominant in developed countries and is the most widely studied
clade, non-subtype B HIV-1 are responsible for .90% of HIV
infections [3,4] Subtype C dominates in prevalence (.50% of
infections worldwide) due in part to epidemics in India, China,
and southern African countries (South Africa, Zimbabwe,
Botswana, Zambia, Namibia, Malawi) [3,4]. In South America,
the HIV-1 epidemic has been well characterized with subtype B
HIV-1 found in the northern Pacific and Caribbean coastal
countries (Venezuela, Columbia, Ecuador, Peru) whereas in the
Southern cone (i.e. Argentina, Chile, Paraguay, and Uruguay) the
epidemic is more diverse with a higher HIV-1 prevalence. In
southern Brazil and Argentina [8,9] subtype B, C, and F as well as
B/C and B/F recombinants are the most prevalent (Figure 1).
Intersubtype BF recombinants were first reported as a CRF
(CRF12_BF) in Argentina and Uruguay in 2001 [10], followed by
other novel BF CRFs in Brazil, Uruguay and Chile (i.e.
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CRF17_BF, [10]; CRF28_BF, CRF29_BF [11]; CRF38_BF [12];
CRF39_BF, CRF40_BF [13], CRF44_BF; CRF46_BF [14].
CRF12_BF, CRF38_BF, and related BF recombinants appear to
have originated in the late 1970s and early 1980s, dates which
coincide with the beginning of the local epidemic [15,16]. In the
HIV-infected population of Brazil (with the exception of southern
Brazil; Figure 1), subtype B (71%) dominates over a lower
prevalence of intersubtype BF recombinants (12%), subtype C
(10%), subtype F (5%) and other subtypes/intersubtypes (2%) [17–
19]. In contrast, intersubtype BF recombinant (56.7%) are found
at high prevalence in HIV-infected Argentineans with subtype B
(34.5%), F and other subtypes/intersubtypes (,5%) observed at
low frequency [20–23] (Figure 1). About 50% of these Argenti-
nean intersubtype BF-like viruses are related to, but distinct from
CRF12_BF [10,20,22]. Notably, most BF recombinants appear
unique, but share a number of breakpoints with CRF12_BF [22].
Thus, previous or continuous super-infections involving
CRF12_BF and/or other B, F, or BF recombinant viruses results
in circulation of multiple BF recombinants which may be better
defined as unique recombinant forms (URFs) rather than CRFs.
This subtype/recombinant diversity and dynamics is quite unique
to the Argentinean epidemic. In this study, the full genome
sequences revealed that all of the 18 BF recombinant HIV-1
isolates from Buenos Aires, Argentina were URFs and not CRFs.
Based on the dominance of BFs in the Argentinean epidemic,
Sanabani et al. (2006) [24] have proposed that these recombinants
may have higher replicative fitness than ‘‘pure’’ subtypes B and F.
However, aside from the fitness studies of CRF02_AG versus
Figure 1. Changes in the prevalence of HIV-1 subtypes and recombinant forms during the past ten years in Buenos Aires, Argentina
(white) and Rio Grande do Sol, Brazil (gray). Rio do Sol is located in the most southern part of Brazil while Buenos Aires is in north eastern
Argentina. Both regions are located close to each other and share a common characteristic in that they harbor dominant and evolving recombinant
forms. The prevalence numbers shown were obtained by combining the subtype distribution from published reports originating in these 2 regions.
Only samples with a known sampling date were included in the analyses.
doi:10.1371/journal.pone.0092084.g001
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subtype A or G, there are no other comparisons of replicative
fitness between recombinant HIV-1 and their parental isolates.
Two studies have examined potential phenotypic differences
among BF viruses [25,26] and suggested that HIV-1 BF strains
might have a higher replicative fitness over subtypes B and F HIV-
1 isolates. In an effort to understand the high prevalence of
intersubtype BF recombinants in Argentina, we compared ex vivo
‘pathogenic’ or replicative fitness of primary HIV-1 isolates of
subtype B, F, C, and intersubtype BF recombinants derived from
chronically infected patients. Fitness of these primary HIV-1
isolates was determined by direct head-to-head virus competitions
in human peripheral blood cells (PBMCs) of HIV-negative donors.
We discovered that the BF recombinants were of equal or lower




Confidential one-on-one interviews were conducted onsite by
health care workers. During these encounters, the study was
explained and subjects were invited to participate. Only those
subjects who were willing to participate were provided with a
written informed consent, enrolled, and sampled. All procedures
were approved by the Independent Research Ethics Committee,
School of Medicine, University of Buenos Aires (CIEI-FM-UBA),
Office for Human Research Protection (OHRP) reference
numbers IORG#0004063 and IRB#00004817.
Patients, Sample Collection, Viral Load Determination
and CD4 Lymphocytes Count
Patients were sampled from September 2002 to July 2004 from
two medical facilities in Buenos Aires: namely the Hospital de Agudos
José Marı́a Ramos Mejı́a, (n = 15), a voluntary counseling and testing
center where routine HIV testing is performed and the ‘‘National
Reference Center for AIDS, School of Medicine, University of
Buenos Aires’’ (n = 13) where patients are monitored routinely for
viral load and CD4 cell count as standard-of-care. Subjects
attending these centers were from the city of Buenos Aires and
nearest suburbs. Clinical records were reviewed to confirm that
these patients were antiretroviral naı̈ve.
Whole blood samples were collected and an aliquot was used for
CD4 determination. Briefly, absolute count of CD4+ T-lympho-
cytes (cells/ul) from peripheral whole blood was determined in
each HIV-1-infected patient by flow cytometry using a Coulter XL
(Beckman) instrument (Table 1). Remaining blood was separated
into plasma and buffy coat. Viral load in plasma was assessed by
the branched DNA technology [VERSANTH HIV-1 RNA 3.0
Assay (b-DNA)] with a detection range of 50–500,000 HIV-1
RNA copies/ml (Table 1).
Virus Isolation, Co-receptor Usage and Titration
PBMCs isolated from HIV infected patients were co-cultivated
with uninfected PBMCs from a healthy donor, as described
previously [27]. Briefly, patient and uninfected cells were
separately stimulated with 2 mg/ml phytohemagglutinin (PHA;
Gibco, BRL) in RMPI medium for 2 to 3 days, and further
maintained in complete RPMI medium containing 10% fetal
bovine serum, 1 ng of recombinant interleukin (IL-2 invitrogen),
100 U/ml penicillin, and 100 mg/ml streptomycin (Cellgro)].
Subsequently, 1.56106 stimulated cells from uninfected donors
were co-cultured, in 24-well tissue culture plates, with 1.56106
PBMC from HIV-1-infected patients. On day 4, 7, 11, 14 and 18,
supernatant was harvested from each well to assess radioactive
reverse transcriptase (RT) activity. On day 7 and 14, 1.56106
PHA-stimulated PBMC from the HIV-negative donor were
thawed from frozen aliquots (derived from the same donor and
blood draw) and added to each well/co-cultivation. Cell-free
supernatants were harvested at peak viremia, as measured by a
RT assay, centrifuged and stored at 280uC until subsequently
needed. Twenty eight primary HIV-1 isolates from Argentina
were obtained from this process. Two subtype F reference strains
CA20 and VI850 were kindly provided by Dr. Guido Vanham
(Institute of Tropical Medicine in Antwerp, Belgium). The other
subtype reference strains (C-97ZA003, C-96USNG58, C-
93MW959, F1-093BR020_1) were obtained from the National
Institutes of Health AIDS Research and Reference Reagent
Program (Table 1).
To determine co-receptor usage, U87 cell lines (human glioma
cell line) expressing CD4 and either CCR5 or CXCR4 chemokine
receptor (obtained from D. Littman and the AIDS Research and
Reagent Program) were maintained in Dulbecco Modified Eagle
Medium (DMEM; Cellgro) supplemented with 15% FBS, 100 U/
ml penicillin, 100 mg of streptomycin, and 300 mg/ml geneticin
(G418; Gibco-BRL) and 1 mg/ml puromycin (Life Technologies,
Inc.) to retain receptor and co-receptor expression, respectively.{-
Deng, 1996 5706/id} Co-receptor usage was then assessed by
infecting 2.56103 U87.CD4 cells expressing either CCR5 or
CXCR4, in parallel, with each viral stock, in 48-well plates, as
described previously [28]. Virus production was determined by
assaying RT activity in the cell-free supernatants at days 3, 5, 7
and 9. Finally, CXCR4-usage was confirmed by infection of the
HTLV-1-transformed MT2 cell line as described [29] (Tables 1
and 2).
The tissue culture infectious dose for 50% infectivity (TCID50)
values were determined by serially diluting each stock of HIV-1
isolate in triplicate and infecting 105 stimulated PBMCs in a 96-
well flat-bottom plate. Infectivity in each well was tested by the
radiolabeled RT assay [28], and the TCID50 assay end point was
determined on day 10. TCID50 values was calculated as infectious
units per milliliter (IU/ml) using the Reed and Muench method
[30].
DNA Extraction, PCR, Sequencing and Phylogentic
Analysis
DNA was extracted from PBMC of each HIV-1-infected patient
with the QIAamp DNA Blood Mini Kit (Qiagen). Nested PCR
was performed on extracted DNA to obtain several non-
contiguous fragments spanning various regions of the HIV-1
genome or the full length genome of isolates. Primers used for
these amplifications are available upon request. HIV-1 PCR
products were purified using the Qiaquick DNA purification kit
(Qiagen) and then sequenced in both directions using an ABI
PRISM 3100 Genetic Analyzer (Applied Biosystems). Chromato-
grams were manually edited for alignment by using Sequencher
4.10.1 Software (Gene Codes) and Vector NTI suite.
Nucleotide sequences were aligned using Clustal X Multiple
Alignment neighbor joining protocol version 7.0.5.3. Alignments
included a representative set of known HIV-1 subtype reference
sequences from the Los Alamos HIV Sequence Database.
Neighbor-joining (NJ) trees were constructed under the Kimura
2-parameter model with the MEGA3 program. The codon
alignment was performed using Gene Cutter tool available at
the Los Alamos National Laboratory website (www.hiv.lanl.gov/
content/sequence/GENE_CUTTER/cutter.html). Each HIV se-
quence was analyzed for recombination patterns using Simplot
version 3.5.1 [31] with a bootscan sliding window of 300
nucleotides in 20 nucleotide steps (100 bootstrap replicates 50%
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consensus) [32]. Only sequences with bootstrap values above 75%
throughout the scanned sequence and in which a fragment of .
200 bp was shown to belong to a discordant subtype were
considered recombinant forms. The Genotyping tool at the
National Center for Biotechnology Information [33] and the
jumping profile Hidden Markov Model (jpHMM) [34] were used
to confirm recombination breakpoints. pol gene sequence from
each sample (2253–3749, HXB2 numbering) was analyzed for
drug resistance mutations, using the Stanford University calibrated
population resistance tool (http://cpr.stanford.edu/cpr/), which
provides a suitable approach for general batch-analysis of HIV-1
pol gene sequences (Table S1).
Sequence Data
Sequences generated from this study have been submitted to the
GenBank under the accession numbers KJ569150–KJ569178.
Genotypic Determination of Viral Tropism
In order to predict genotypic viral tropism and confirm
phenotypic co-receptor usage, we analyzed V3-loop sequences
from each sample (HXB2 gp160 amino acids 296–334) using the
Position-Specific Scoring Matrix (PSSM) (http://indra.mullins.
microbiol.washington.edu/webpssm/) and geno2pheno [co-recep-
tor] (g2p) (http://coreceptor.bioinf.mpi-inf.mpg.de/index.php) as
well as detecting the presence of positively charge amino acids at
codons 11 and/or 25 of the V3-loop (HXB2 gp160 positions 306
and 322, respectively). PSSM analysis was performed using
subtype B X4R5 matrix whereas for g2p, significance levels were
set to the optimized cutoffs based on clinical analyses from
MOTIVATE (2% and 5.75% false positive rates) [35].
Ex vivo Growth Competition Assays
The ex vivo pathogenic fitness of each virus was determined by
performing duplicate pair wise dual infection/competitions
experiments as described previously [36]. Briefly, Argentinean
HIV-1 primary isolates were competed against each other as well
as subtype reference strains (Table 1). Virus was added alone or in
pairs to 26105 PHA/IL-2 PBMC from HIV-1-seronegative
healthy donors at an equal multiplicity of infection (MOI) of
0.0005 (IU/cell) [36,37]. All PBMCs for these fitness studies and
for TCID50 determination were obtained from one donor and one
blood draw of 500 ml. Assays were carried out in duplicates in 48-
well cell culture plates. Full pair wise competitions were performed
involving R5 vs R5-using isolates or X4 vs X4-using isolates
(Table 1). The dual tropic primary isolates were also competed
against specific R5 and X4 primary isolates. Finally, we performed
a subset of dual infections to compete X4 versus R5 HIV-1 isolates
in PBMC cultures [38,39]. Virus mixtures were incubated with
PBMC at 37uC in 5% CO2, washed with phosphate buffered
saline (PBS) 48 hours post-infection and then resuspended in
complete medium. Cell-free supernatant was collected and assayed
for RT activity 5, 7, 9, 11 and 13 days post-infection. Two aliquots
of supernatants and two aliquots of cells were harvested at day 13
post infection and stored at 280uC for subsequent analysis.
Heteroduplex Tracking Assay (HTA) and Estimation of
Viral Fitness
For all dual and mono-infected cultures, proviral DNA was
extracted from lysed PBMC using QIAamp 96 DNA Blood Kit
(Qiagen). Viral DNA was isolated from infected cells and a
fragment of env was PCR-amplified, as described previously
[39,40]. Briefly, a set of external primers EnvB and ED14, and
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region [53]. Nested PCR products of the env gene were analyzed
by the heteroduplex tracking assay (HTA) to determine the
amount of virus produced in the dual infection/competition
experiments [39]. The same genomic region (env C2-V3) was
PCR-amplified from different subtype-specific HIV-1 env clones
[subtype A RW020 and SF170, subtype C BR025, subtype E
TH22 and CAR7] [41] for use as DNA probes. However, in this
case, the E80 primer was radiolabeled with T4 polynucleotide
kinase and 2uCi of 59-[c32P] ATP, prior to amplification, as
described [39]. At least two DNA probes in separate HTAs were
used to determine relative virus production in each dual infection.
Probes and PCR products were mixed, denatured and annealed
on a 6% polyacrylamide gel. Heteroduplexes corresponding to
each virus in a given competition were quantified using a
Molecular Imager FX (Bio-Rad) imager. The final ratio of the
two viruses produced in a dual infection was estimated by
comparing the virus production in the competition to the virus
production in the monoinfection. Production of individual HIV-1
isolates in a dual infection (f0) divided by its initial proportion in
the inoculum (i0) is referred to as the relative fitness (w = f0/i0).
Thus, the ratio of the relative fitness values of each HIV-1 variant
in the competition is a measure of the fitness difference (WD)
between both HIV-1 strains (WD = WM/WL), where WM and WL
correspond to the relative fitness of the more and less fit viruses,
respectively [39].
Statistical Analysis
Statistical analyses were performed using GraphPad Prism 4
(GraphPad Software, USA). Two-tailed Student’s t tests were used
to compare patients’ mean age. Two-tailed Mann-Whitney tests
were used to compare viral load values and CD4 cell counts. Two-
sided Fisher’s exact tests were used to compare winner/loser
proportions in competitions between two groups of viral isolates.
All tests were considered significant when p,0.05.
Results
Patient Clinical Characteristics
Twenty-eight HIV isolates obtained from 28 patients at various
stages of HIV disease were used in this study. The mean age of
subjects infected with HIV-1 subtype B and BF-like recombinants
was similar (mean age 38.7 and 37.7 years, respectively,
p = 0.1669, Student’s t test, unpaired, two-tailed) while the mean
age for all 28 subjects was 38.1 (Table 1). Viral load values were
also similar for both groups; subtype B and BF strains (1.26105
and 1.46105 copies/ml respectively) (Table 1). Comparison of
CD4 cell counts between subtype B and BFs suggested all subjects
were in late stages of disease (187 and 230 cells/ml respectively,
p = 0.9399, Mann-Whitney test, two-tailed) (Table 1). Further-
more, no significant association could be established between
patient viral load values (VL) and viral tropism (VL: R5 vs. X4; see
below), nor between VL and subtype (data not shown).
Because drug resistance mutations affect replicative fitness of
viral isolates [61], all primary isolates were screened for the
presence of drug resistance mutations in the pol gene using the
Stanford Drug Resistance Database tool (http://cpr.stanford.edu/
cpr/). Two of the 28 HIV-1 isolates harbored mutations associated
with high level resistance to protease inhibitors (PIs) and to reverse
transcriptase inhibitors (RTIs). Namely, isolates B524 carried
mutations V82A, I84V, L90M in PR, and K103N, P225H in RT
while isolate BF819 had mutations D30N, N88D in PR and
E101E/K and M184V in RT (Table S1).
Figure 2. Genotypic Characterization of HIV-1 primary isolates from Argentina. Phylogenetic trees were constructed for (a) partial pol
(2253–3749, HXB2) and (b) vpu to env (5968–9092, HXB2) of Argentinean primary isolates. Sequences were aligned using Clustal X and trees
constructed by neighbor joining method under the Kimura 2-parameter model. (c) Sequences were aligned and bootscanned as described in
materials and methods to determine recombination sites. Sequences in green represent the subtype F1 regions and in blue-subtype B. Regions in the
genome that were not sequenced are represented by empty boxes. The gray shading represents those sequences used for the phylogenetic trees in
2a and b respectively.
doi:10.1371/journal.pone.0092084.g002
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Phylogenetic Characterization of Argentinean HIV-1
Isolates
Sequencing of two genomic fragments from a single virus
facilitates subtype classification, detection of recombination sites
within the HIV genome, and mapping of these recombination sites
to the common breakpoints found in the BF CRF. Neighbor-
joining (NJ) phylogenetic trees of partial pol (2253–3749, HXB2
numbering) and vpu-env (5968–9092, HXB2 numbering) sequences
of these 28 Argentinean HIV-1 isolates predicted 9 (32.1%)
subtype Bs, 18 (64.3%) intersubtype BF recombinants, and 1
(3.2%) subtype C (Fig. 2a, b and shaded regions of Fig. 2c;
Table 1). Six samples (BF329, BF549, BF559, BF640, BF714,
BF992) had discordant phylogenetic clustering patterns in the pol
compared to the vpu-env sequences suggesting that a recombination
event occurred between or within these two genes (Fig. 2a and b).
Considering earlier reports of diverse BF strains circulating in
Argentina [22,42], we performed bootscan analyses on the pol and
vpu-env sequences (see Materials and Methods). These algorithms
confirmed the initial classification into B, F, and BF subtypes/
recombinant forms as well as identified probable recombination
sites, almost all of which were unique to the known BF CRFs
(CRF12,17, 38, 39, 40, 42, 44, 46, and 47).
Near full length sequencing of 18 of these 28 samples confirmed
results from partial pol and env sequencing, i.e. the BF recombinant
patterns were different from the two main BF recombinants
CRF12_BF and 17 (Fig. 2c) as well as the other BF CRFs that
circulate in Argentina or other regions of South America (not
shown in Fig. 2c). Only one BF recombinant, BF549, had a ‘‘pure’’
subtype F sequence for the vpu to env region whereas the other BF
isolates had a mosaic rev and/or env composed of both subtype B
and F sequences (Fig. 2c).
Isolation of Primary Isolates, Co-receptor Usage and V3-
loop Properties
Twenty-eight primary HIV-1 strains were obtained by PBMC
co-cultivation using blood samples derived from HIV-1 positive
patients in Buenos Aires, Argentina (Table 1). Co-receptor usage
was assessed by infecting U87.CD4 cells expressing either CCR5
or CXCR4. Of the 28 primary HIV-1 isolates, 20 could only
replicate in U87.CD4.CCR5 cells (R5-tropic), 4 only infected
U87CD4.CXCR4 cells, and 4 were dual/mixed tropic (R5/X4)
(Table 1 and 2). Additionally, only B553, B775, BF559, BF819,
BF027, BF134, BF555, and BF640 replicated in MT-2 cells, i.e.
the same viruses designated X4 or R5/X4 using the U87.CD4 co-
receptor usage assay. The X4 and R5/X4 HIV-1 isolates were
derived from late stage disease and typically had viral loads (.105
copies/ml) and low CD4 cell counts (,200 cells/ml) (values not
available for all patients at the time of sample collection). Two X4
isolates were subtype B and two, were BF recombinants whereas
all four dual tropic viruses were BF isolates (Table 1 and 2).
The co-receptor usage of these 28 HIV-1 Argentinean isolates
was confirmed by inputting the Env V3 amino acid loop sequence
into various algorithms: the net amino acid charge, the 11/25 rule,
Position-Specific Scoring Matrix (PSSM), and geno2pheno. It is
important to note that PSSM and geno2pheno provide the highest
predictive values for co-receptor usage with subtype B HIV-1
sequences as compared with other HIV-1 subtypes. The X4 and
R5/X4 HIV-1 isolates had the highest positive net amino acid
charge in the V3 loop when compared to that of the R5 viral
isolates (mean X4 net charge = 6.75 vs. mean R5 net
charge = 4.69, p = 0.0006, Student’s t test, unpaired, two-tailed).
Three of eight CXCR4-using viruses (B775, and BF559, and
BF555) had a positively charged amino acid at position 11 or 25
(306 and 322 in HXB2 Env amino acid numbering), (Table 2). In
subtype B, over 90% of the X4 or dual tropic HIV-1 isolates have
a positively charged amino acid at positions 11 and 25.
Furthermore, the R5 isolate B563 had an Arginine at position
25, which predicts CXCR4 usage with 80–90% specificity [35].
Finally, PSSM and geno2pheno correctly predicted co-receptor
usage for 26 and 28 HIV-1 isolates. Only R5 BF992 and X4
BF819 were incorrectly predicted as X4 and R5 by PSSM
(respectively) whereas R5-B563 and X4-BF819 were wrongly
Figure 3. Comparing the relative replicative fitness difference
(WD) of HIV-1 subtype B and BF recombinants from Argentina
in direct competitions. Subtype B strains a) B271 b) B524, c) B542 d)
B563 e) B735 f) B872 g) B958 were competed against CRF-BF-like
isolates (BF116, BF118, BF119, BF303, BF329, BF333, BF456, BF461,
BF549, BF714, BF955, BF992) in PHA-stimulated, IL2-treated PBMCs. The
fitness difference represented on the Y axis ranges from 0.01 to 100.
Bars represent the fitness of the isolates shown on the Y-axis.
doi:10.1371/journal.pone.0092084.g003
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predicted as dual and X4 tropic (respectively) by geno2pheno
(Table 2). None of these ‘‘subtype B’’ algorithms were absolute in
predicting co-receptor usage as determined by phenotypic assays.
Limitations in predicting co-receptor usage may relate to the
subtype F V3 loop sequences bore by most BF isolates (Fig. 2b and
c). An antigenically distinct subtype B variant has been described
in Brazil, which has a GWGR rather than GPGR signature motif
at the tip of the V3-loop. This rare variant is found in ,50% of
Brazilian subtype B isolates and has been associated with slower
disease progression [43]. Considering the overlap between the
Argentinean and Brazilian HIV epidemics, we analyzed the
diversity of the V3-loop. Only one of the Argentinean HIV
sequence (BF134) had a GWGR motif, which was also the only BF
strain with a subtype B Env gp120 coding region. The subtype F
V3 sequences of the BF strains had either a GPGR or GPGQ
sequence, the latter being more common for subtype F but
infrequent for subtype B [44].
The N-linked glycosylation site, N301, is part of a highly
conserved NNTR sequence found in the V3 loop of CCR5 tropic
primary isolates [45]. All of the subtype B, F, and BF sequences
had NNTR sequence with the exception of two X4 isolates, which
harbored either NTIKQ (B552, with an isoleucine insertion) and
NKTQ (B775) (Table 2). Aside from N-linked sites at amino acid
position 301, no significant differences were observed in the
sequence lengths of any variable loop or in the number of N-linked
glycosylation patterns in the V1–V5 regions with the Argentinean
subtype B and BF isolates.
Relative Replicative Fitness of Primary Subtype B, C, F
and Intersubtype BF Recombinant HIV-1 Isolates of
Different Phenotypes
In order to determine the ex vivo pathogenic fitness of primary
R5 and X4 subtype B, C and intersubtype BF recombinant isolates
from Argentina, nearly 700 dual infection/competitions experi-
ments were performed in PHA stimulated human PBMCs using
the 28 primary HIV-1 isolates (described above) and 6 reference
strains of subtypes C (n = 3); F1 (n = 2), and F2 (n = 1) (Table 1).
Full pairwise competition experiments were performed with the 25
primary R5 isolates and the 9 primary X4- and X4/R5-tropic
isolates (Figures 3–7). The fitness difference, WD is defined as the
fitness of a B isolate over the fitness of BF isolate or C isolate in
PBMC competitions (Fig. 3 and 4, respectively). In Fig. 3, we show
that the replicative fitness of each R5 subtype B isolate (y axis of
panels A–G) is, on average, similar to each of the 12 BF isolates in
Figure 4. Relative fitness difference (WD) between Argentinean subtype B strains a) B271, b) B563 c) B735 d) B872, e) B958 and
Subtype C strains C674 (Argentina), C5, C8, C9 (reference strains). Competitions were performed in PHA/IL2 treated PBMCs as in Figure 3.
The fitness difference shown on the Y axis ranges from 0.01 to 100. Bars represent the fitness of the isolates shown on the Y-axis.
doi:10.1371/journal.pone.0092084.g004
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these pairwise competitions. Only one BF isolate (BF549) is
consistently more fit that all the B isolates (Fig. 3a–g) and other BF
strains (Fig. S1a). Intersubtype BF recombinants and subtype B
isolates had nearly equal number of ‘‘wins’’ in direct head-to-head
competitions (BF wins: 55.95%, n = 47 while B wins: 44.05%,
n = 37, p = 0.1647). However, as shown in Fig. 4, the subtype B
and BF isolates clearly out-compete the subtype C HIV-1 isolates
with C viruses winning only one of 22 head-to-head competitions
(p,0.0001, two-sided Fisher’s exact test) confirming previous
observations that subtype C strains are less fit than most HIV-1
group M strains [36,40,46]. The only Argentinean subtype C
isolate in our panel, C674 was the least fit compared to the other 3
C HIV-1 isolates derived from South Africa, Nigeria and Malawi
(Fig. 4).
HIV-1 subtype F1 is a parental subtype of BF recombinants.
However, ‘‘pure’’ subtype F HIV-1 is now rare in Argentina as
reflected by its absence in our set of Argentinean primary isolates
and recent molecular epidemiology studies [16,42] (Fig. 1). We
therefore included a CCR5-using subtype F1 primary isolate,
CA20 from Cameroon and subtype F2, VI850 from the
Democratic Republic of Congo (DRC) for competitions against
6 Argentinean subtype B (Fig. 5a and b) and 8 BF strains (Fig. 5c
and d). The sub-subtype F1 is most related to South American F
isolates and the F segments in BF recombinant genomes. The F1
isolate, CA20 was of equal or slightly greater fitness than the
subtype B and BF isolates whereas the F2 isolate, VI850 was
slightly less fit and lost the majority of competitions against the
subtype B and BF isolates from Argentina. Nonetheless, there was
no significant difference in replicative fitness between any of these
subtype B, F, or BF HIV-1 isolates.
The mean intra- and intersubtype relative values were plotted
for each of the B and BF isolates (Fig. 6) to obtain a clear
representation of relative replicative fitness in human PBMCs. In
Fig. 6, the mean intra-subtype/-recombinant relative fitness values
(y axis) represents the average fitness of each B (or BF) isolate
against each of the other B (or BF) isolates. Inter-subtype/-
recombinant (x-axis) represents the average fitness of each B (or
BF) isolate against each of the BF (or B) isolate. When comparing
the intra- and inter-group M and subtype C fitness of 29 primary
HIV-1 isolates in a previous study, we clearly showed that the
Figure 5. Comparing the relative replicative fitness difference (WD) of HIV-1 sub-subtype F1 reference strains; (a) CA20 and (b)
V1850 and Argentinean subtype B (B271, B524, B542, B563, B735 and B872) in direct competitions using PHA/IL2 PBMCs. Similarly,
subtype F (c) CA20 and (d) V1850 were competed against BFs (BF116, BF118, BF119, BF303, BF456, BF549, BF714 and BF955). Bars represent the
relative fitness of the viruses shown on the Y-axis.
doi:10.1371/journal.pone.0092084.g005
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subtype C isolates were on average less fit than any group M
isolate (e.g. subtype A, B, D, and CRF01_AE) (see insert panel A
of Fig. 6). In contrast, the replicative fitness of the subtype B and
BF isolates from the inter-subtype/-recombinant comparisons
overlapped with the intra-subtype fitness comparisons. In other
words, some isolates such as BF549 had both high intra- and inter-
Figure 6. Comparison of intra- and intersubtype fitness of R5 HIV-1 subtype B and various BF recombinants from Argentina. Mean
relative fitness values were determined for each HIV-1 isolate from pairwise competitions between isolates of the same subtype (mean intrasubtype
relative fitness) and of different subtypes (mean intersubtype relative fitness). The mean intrasubtype and intersubtype fitness values for each HIV-1
isolate were then plotted as the x and y coordinates. Subtype B viruses are shown as black filled squares while BF recombinants are indicated by a red
filled square. The mean fitness of subtype B and BF are very similar and also indicated as red and black filled squares respectively. The insert figure
represents the fitness of HIV-1 subtype C relative to group M strains as described in a previous study (Abraha et al, 2009). Subtype C strains (red
squares and triangles) have low mean relative fitness and cluster together (orange oval shade) while group M strains (green dots and tetragon) are
more fit and cluster together as well (green oval shade).
doi:10.1371/journal.pone.0092084.g006
Figure 7. Comparing the relative replicative fitness difference (WD) of syncytium inducing (SI) HIV-1 Argentinean subtype B (a)
B552, (b) B775 and (c) reference subtype F, 93BR020 against BF Argentinean recombinants (BF134; BF559; BF819, BF027, BF555
and BF640) in direct competitions using PHA/IL2 PBMCs. Bars represent the fitness of the viruses shown on the Y-axis.
doi:10.1371/journal.pone.0092084.g007
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subtype/-recombinant fitness but on average the BF isolates were
not more fit than B isolates or vice versa (see mean R5 B fitness vs
mean R5 BF fitness in Fig. 6).
A more limited set of CXCR4-using subtype B (B552, B775)
and BF (BF134, BF027, BF555, BF640) HIV-1 isolates were
available from Argentinean patients for these fitness studies. These
viruses as well as one subtype F X4 reference strain (93BR020)
were used for pairwise competitions in PBMCs (Fig. 7, Fig. S1b).
As described in Fig. 7, it appears that X4 B isolates had higher
fitness than the BF HIV-1 isolates in direct head-to-head
competitions (B wins 10 of 12 competitions, 83%, p = 0.0033).
However, the BF819 isolate is an X4 isolate carrying drug
resistance mutations D30N and N88G in PR and M184V in RT.
The lamivudine-resistant M184V mutations is associated with a
fitness cost [47]. When excluding the BF819 isolate from these
analyses, there was no statistical difference in replicative fitness
between these CXCR4-using subtype B and BF isolates. The sole
subtype F X4 isolate was more fit than all the BF recombinant and
B isolates (not shown). In summary, a total of 40 competitions
between the other two subtype F isolates, 9 subtype B isolates, and
18 BF recombinants show similar replicative fitness (p = 0.129) and
suggest that this X4 subtype F isolate, 93BR020 and the R5 BF549
isolates were outliers with high replicative fitness.
Regardless of subtype, X4 HIV-1 isolates usually replicate faster
and to higher levels than R5 HIV-1 isolates in PBMC cultures
[39,46]. However, as previously reported [36,39,46]), these dual-
infection experiments in PBMC cultures do not represent ‘‘true’’
competitions as R5 and X4 isolates do not compete for the same
susceptible cells. CCR5 and CXCR4 are typically expressed on
different CD4+ T-cells (predominantly on memory and naı̈ve,
respectively) [48] or at different levels in macrophages (higher
CCR5 over CXCR4 levels). In this study, two R5 subtype B and
one R5 intersubtype BF isolate were competed against three X4
primary isolates (1 subtype B and 2 intersubtype BFs isolates). All
X4 isolates out-produced R5 variants, in a subtype independent
manner, further supporting the higher pathogenic fitness of X4
isolates over the R5 HIV-1 isolates in PHA-activated, IL2-
maintained PBMC cultures (Data not shown).
Discussion
In many epidemics around the world, generation and trans-
mission of intersubtype HIV-1 recombinants appears to outpace
the expansion of the ‘‘pure’’ parental subtypes. For example, BC
recombinants are now increasing in prevalence as compared to
subtype B or C HIV-1 isolates in Rio Grande do Sol province in
Brazil [49–51] (Fig. 1). BC recombinant forms (specifically CRF07
and 08) dominate over subtype B’ or C in China [52]. Finally, the
HIV-1 epidemic in Argentina involves a complex mixture of BF
recombinants expanding faster than subtype B infections [42]
(Fig. 1). This increasing prevalence of recombinant forms might
infer greater replicative fitness over the parental HIV-1 subtype in
the epidemic. However, ‘‘fitness’’ in the HIV-1 epidemic is not
necessarily comparable to ex vivo replicative fitness in PBMCs
whereas virulence (i.e. rate of disease progression within a patient)
is a direct correlate of replicative fitness [53]. With the exception of
studies comparing the relative fitness of subtype A, G, and
CRF02_AG HIV-1 isolates [54], [55] ex vivo replicative fitness of
intersubtype HIV-1 recombinants have not been compared to
their parental HIV-1 subtypes in primary human cells.
To obtain a preliminary understanding on how HIV-1
recombination in the epidemic impacts replicative fitness (and
possibly pathogenesis), we compared the ex vivo fitness of reference
subtype F, primary isolates of subtype B, and recombinant BF
HIV-1 from Argentina where a significant emergence of BF
recombinants is recent (mid 1990s–early 2000s) and complex
[42,56], (Fig. 1). Initial V3 loop genotypic analyses of HIV-1 in
Argentina suggested that the epidemic was similar to that in North
America where subtype B was and still is highly prevalent [57].
However, we now know that subtype F HIV-1 may have a longer
history in Argentina, having been introduced between 1975–1980
[56]. Recent studies have shown that the HIV epidemic in
Argentina is dominated by pure subtype B, various BF recombi-
nant forms, and a rare occurrence of subtypes C and F.
Accordingly, we were unable to identify a ‘‘pure’’ subtype F
isolate among 28 HIV infected individuals which is consistent with
recent reports of rare subtype F HIV-1 infections in Argentina
[42,58]. Early in the Argentinean epidemic, subtype B was most
common in men who have sex with men (MSM) and subtype BF
among IDUs and the heterosexually-active population [59,60] but
differential prevalence of subtypes/recombinants in these trans-
mission groups has eroded over the past decade. Despite attempts
to classify the BFs as CRFs, our analyses of 18 full and near full
length BF genomes revealed that most BF breakpoints did not
match the recombination sites used to classify CRF12,17, 38, 39,
40, 42, 44, 46, and 47. In the past, a majority of BF recombinants
isolated from HIV-infected Argentineans have been classified as
CRF12_BF and CRF17_BF based on partial pol sequences
[17,22,42]. We are now analyzing all of the full length BF
sequences in the Los Alamos HIV-1 sequence database (n = .40)
and preliminary results suggest that the vast majority of the BF
strains classified as a CRF might instead be URFs of recent B+F or
BF+B co-infections, the latter being the most likely. We observed
little evidence of an epidemic with stable BF CRFs in Buenos
Aires. These findings are consistent with recent studies showing a
decrease in CRF12_BF prevalence (69% to 46% from 1986–93 to
2001–2008) [42] and an increased prevalence of unique BF
recombinant forms in Argentina (up to 50% infections by
URF_BF) [17,42] (summarized in Fig. 1). The later introduction
of subtype C in Argentina from Brazil has led to the identification
of BC recombinants (which may have originated in Brazil) and of a
complex B/C/F recombinant in one patient [61].
Does the predominance of BF recombinants suggest a better
fitness of these strains? Factors such as founder effects, host
restrictive factors as well as cultural/behavioral factors may affect
differential global spread of HIV variants in the human population
[3,4,62]. We are also adopting infectious disease models to
understand HIV spread in the epidemic [63]. Lower virulence
(related to reduced replicative fitness in PBMCs [64]) leads to
longer asymptomatic infection and increased opportunity for
transmission. Aside from an initial founder event(s), the other key
factor in these models is transmission efficiency related to the
amount of transferred virus (e.g. viral load in donor [65,66]) and
the ability to establish new host infections (e.g. relative replicative
capacity and transmission through mucosal/genital tissue
[36,38,40]. The dominance of BF-like recombinants over subtypes
B, C and F in Argentina may be related to some biological
advantage such as better transmission efficiency coupled with
weaker virulence over the parental ‘‘pure’’ subtypes B and F. A
second but not exclusive factor relates to the timing of founder
events into the Argentinean population, and possibly into different
transmission groups [49]. As described above, with the continuous
emergence of new BF recombinants, these different transmission
groups (e.g. IV drug users, heterosexuals, and MSMs) have now
mixed and the BF epidemic in Argentina is now driven by
heterosexual transmissions. This study only suggests that the
similar replicative fitness of B, F, or BF HIV-1 isolates may relate
to similar rates of disease progression (as determined by increasing
HIV Fitness of B and BF Strains in Argentina
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viral loads and decreasing CD4 cell counts). Thus, we propose that
the increased spread of BF isolates in the Argentinean epidemic
may be related to better transmission opportunity and/or
efficiency of BF over B or F HIV-1 isolates. We are currently
testing transmission efficiency in our ex vivo transmission models
involving infections of human penile, cervical, vaginal, and rectal
explants.
After .700 head-to-head competitions between 9 B, 18 BF, 3 F,
and 4 C HIV-1 isolates (28 from Argentina), it was clear that
subtype B and BF HIV-1 isolates had similar replicative fitness in
human PBMC cultures. Subtype C HIV-1 isolates were less fit
than all of the 27 B, BF, and F HIV-1 isolates, which remained
consistent with multiple studies showing poor replicative fitness of
subtype C HIV-1 compared to any other group M HIV-1 isolate
(derived from .2000 pairwise competitions employing over 50
primary HIV-1 isolates) [36,40,46]. Our studies and those of
others have suggested that HIV-1 subtype F isolates may be of
slightly higher replicative fitness than the majority of group M
isolates. The proposed higher replicative capacity of F and BF
HIV-1 strains is based on specific gene sequence or other genetic
factors. One study suggested that the subtype F long terminal
repeat (LTR) showed greater transcriptional activation than the
LTRs of subtype B [25], possibly leading to higher levels of virus
production. Aulicino et al (2007) [58] examined 40 Argentinean
vpu sequences of BF strains and revealed a high substitution rate
(,1161023 substitution per site per year) than that observed
among subtype B strains [67]. These studies were limited to one or
few B, BF, or F sequences and did not examine the effects of these
gene regions/sequences in the context of the entire virus isolate.
Nonetheless, both studies provide some evidence for increased
subtype F fitness over subtype B HIV-1 isolates.
Based on the cumulative data from over 5000 pairwise
competitions in PBMCs [36,40,46], we now rank replicative
fitness of subtypes and dominant CRFs as follows: B = D = F.
CFR02_AG$A = CRF01_AE..C. In addition there is a strong
correlation between relative replicative fitness in PBMCs and
virulence in humans. Interestingly, the subtypes of highest
replicative fitness (B, D, and F) are also the viruses expanding
the slowest in numerous regional pandemics resulting in apparent
shifts in the dominant subtypes, e.g. CRF01_AE or URFs over
subtype B in Thailand, subtype C-containing URF and subtype C
over subtype B in Brazil, and BF URFs over subtype B and F in
Argentina. We suspect that these subtype/CRFs/URFs of lower
virulence are expanding due to greater opportunity for transmis-
sion and retention of high transmission efficiency. Preliminary
studies suggest that all HIV-1 subtypes in group M have similar
transmission fitness when employing human genital tissue as a
model for primary infection. As with the near extinction of HIV-1
subtype F in the Argentinean HIV-1 epidemic over the past 40
years, the dominance of subtype F HIV-1 over other subtypes has
also decreased in Romania [68] and is almost absent in Cameroon
(5% in 1999); [27] despite the moderate frequency of subtype F1
(17% of all HIV infections) during the late 80’s and early 90’s [69].
Increase in prevalence and new infections by a specific subtype
may simply be due to founder events in a specific transmission
group. Nonetheless, we consistently observe that HIV-1 subtypes
(D, F, G, and CRF01_AE) that have decreased in prevalence (in
Uganda, Romania/Argentina, Cameroon, and Thailand, respec-
tively) also have the highest ex vivo replicative fitness.
Conclusion
The present study suggests that BF recombinants circulating in
Buenos Aires, Argentina have multiple recombinant structures
which most likely resulted from continuous dual/superinfection
between B and BF. Further, similar replicative fitness between
subtypes B and BF HIV-1 isolates implies that recombination of
the parental HIV-1 isolates does not necessarily increase
replicative fitness. Initial dual infection or superinfection may
result in higher fitness based on immune escape, host adaptation,
and/or increase replicative fitness. Subsequent transmission of the
recombinant form (e.g. BF) may select for factors associated with
high transmission efficiency, which appear to be different than
those factors governing replicative fitness in PBMCs. It is worth
noting that CRF02_AG, another dominant recombinant was
found to be more fit than its parental subtypes A and G, [54,55]
suggesting that this higher replicative fitness may be associated
with its dominance in the African HIV epidemic. However, the
origin of CRF02_AG (or sub-subtype A3) dates back to the start of
the HIV-1 pandemic in the Congo basin whereas our BF strains
may have originated from very recent dual or super infections in
Argentina [15]. Following approximately 50 years of evolution, the
replicative fitness of CRF02_AG may reflect the changes derived
from the original recombination as well as the accumulation of
stable substitutions within the genome. With the analyses of the BF
recombinants, evolution may be limited to just one or few
transmission events.
Supporting Information
Figure S1 Fitness difference for pairwise competition
with R5 and X4 HIV-1 isolates. Fitness differences (WD) for
pairwise competition with A) R5 and B) X4 HIV-1 isolates are
shown as the relative fitness of the ‘‘column’’ isolate over the
‘‘row’’ isolate. Gray boxes represent intra-subtype fitness differ-
ences while unshaded boxes represent inter-subtype fitness
differences among HIV-1 patient’s isolates and reference strains
from subtype B (bold italic), intersubtype BF recombinants (bold),
subtype C (italic) and subtype F (normal).
(XLSX)
Table S1 Drug resistance mutations: calibrated popu-
lation resistance tool from Stanford University was used
to evaluate the presence of drug resistance mutations in
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